US20050244400A1 - Acid alpha-glucosidase and fragments thereof - Google Patents

Acid alpha-glucosidase and fragments thereof Download PDF

Info

Publication number
US20050244400A1
US20050244400A1 US11/057,058 US5705805A US2005244400A1 US 20050244400 A1 US20050244400 A1 US 20050244400A1 US 5705805 A US5705805 A US 5705805A US 2005244400 A1 US2005244400 A1 US 2005244400A1
Authority
US
United States
Prior art keywords
gaa
igf
amino acid
receptor
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/057,058
Other languages
English (en)
Inventor
Jonathan LeBowitz
John Maga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Zystor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zystor Therapeutics Inc filed Critical Zystor Therapeutics Inc
Priority to US11/057,058 priority Critical patent/US20050244400A1/en
Assigned to ZYSTOR THERAPEUTICS, INC. reassignment ZYSTOR THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEBOWITZ, JONATHAN, MAGA, JOHN
Publication of US20050244400A1 publication Critical patent/US20050244400A1/en
Priority to US11/900,659 priority patent/US7785856B2/en
Assigned to BIOMARIN PHARMACEUTICAL INC. reassignment BIOMARIN PHARMACEUTICAL INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZYSTOR THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds

Definitions

  • Acid alpha-glucosidase is a lysosomal enzyme that hydrolyzes the alpha 1-4 linkage in maltose and other linear oligosaccharides, including the outer branches of glycogen, thereby breaking down excess glycogen in the lysosome (Hirschhorn et al. (2001) in The Metabolic and Molecular Basis of Inherited Disease, Scriver, et al., eds. (2001), McGraw-Hill: New York, p. 3389-3420). Like other mammalian lysosomal enzymes, GAA is synthesized in the cytosol and traverses the ER where it is glycosylated with N-linked, high mannose type carbohydrate.
  • the high mannose carbohydrate is modified on lysosomal proteins by the addition of mannose-6-phosphate (M6P) which targets these proteins to the lysosome.
  • M6P mannose-6-phosphate
  • the M6P-modified proteins are delivered to the lysosome via interaction with either of two M6P receptors. The most favorable form of modification is when two M6Ps are added to a high mannose carbohydrate.
  • Pompe disease a disease also known as acid maltase deficiency (AMD), glycogen storage disease type II (GSDII), glycogenosis type II, or GAA deficiency.
  • ASD acid maltase deficiency
  • GSDII glycogen storage disease type II
  • GAA deficiency The diminished enzymatic activity occurs due to a variety of missense and nonsense mutations in the gene encoding GAA. Consequently, glycogen accumulates in the lysosomes of all cells in patients with Pompe disease. In particular, glycogen accumulation is most pronounced in lysosomes of cardiac and skeletal muscle, liver, and other tissues. Accumulated glycogen ultimately impairs muscle function. In the most severe form of Pompe disease, death occurs before two years of age due to cardio-respiratory failure.
  • M6P-dependent delivery of recombinant GAA to lysosomes is not efficient, requiring high dosages and frequent infusions. Accordingly, there remains a need for new, simpler, more efficient, and more cost-effective methods for targeting therapeutic GAA enzymes to patient lysosmoes.
  • the present invention permits M6P-independent targeting of human GAA or GAA-like enzymes to patient lysosomes by using a peptide tag-based targeting strategy. As a result, the present invention provides efficient delivery of GAA or GAA-like enzymes into target cells.
  • the invention relates, in part, to the discovery that GAA can be expressed recombinantly using a plurality of open reading frames encoding polypeptides representing different portions of the GAA protein. When provided together, the resulting polypeptides can cooperate to provide the desired enzymatic activity.
  • the present invention in one aspect relates to a nucleic acid sequence (such as a DNA sequence) encoding an open reading frame of a polypeptide including an amino acid sequence at least 50% identical (e.g. at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% identical) to amino acid residues 70-790 of human GAA or a fragment thereof.
  • the open reading frame does not include an amino acid sequence at least 50% identical (e.g. at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% identical) to amino acid residues 880-952 of human GAA.
  • the invention in another aspect, relates to a nucleic acid sequence (such as a DNA sequence) encoding an open reading frame of a polypeptide including an amino acid sequence at least 50% identical (e.g. at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% identical) to amino acid residues 880-952 of human GAA or a fragment thereof.
  • the open reading frame does not include an amino acid sequence at least 50% identical (e.g. at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% identical) to amino acid residues 70-790 of human GAA.
  • the invention also relates to cells containing one or both such nucleic acid sequences.
  • a nucleic acid of the invention also encodes a peptide tag fused to the GAA polypeptide.
  • a preferred peptide tag is a ligand for an extracellular receptor.
  • a peptide tag is a targeting domain that binds an extracellular domain of a receptor on the surface of a target cell and, upon internalization of the receptor, permits localization of the polypeptide in a human lysosome.
  • the targeting domain includes a urokinase-type plasminogen receptor moiety capable of binding the cation-independent mannose-6-phosphate receptor.
  • the targeting domain incorporates one or more amino acid sequences of IGF-II (e.g.
  • a peptide tag is fused directly to the N- or C-terminus of the GAA polypeptide.
  • a peptide tag is fused to the N- or C-terminus of the GAA polypeptide by a spacer.
  • a peptide tag is fused to the GAA polypeptide by a spacer of 10-25 amino acids.
  • a peptide tag is fused to the GAA polypeptide by a spacer including glycine residues. In another specific embodiment, a peptide tag is fused to the GAA polypeptide by a spacer including a helical structure. In another specific embodiment, a peptide tag is fused to the GAA polypeptide by a spacer at least 50% identical to the sequence GGGTVGDDDDK.
  • the invention also relates to polypeptides encoded by the nucleic acids of the invention and to pharmaceutical preparations incorporating those polypeptides.
  • the invention also relates, in part, to an appreciation of particular positions of GAA to which a peptide tag can be fused. Accordingly, in one aspect the invention relates to a targeted therapeutic including a peptide tag fused to amino acid 68, 69, 70, 71, 72, 779, 787, 789, 790, 791, 792, 793, or 796 of human GAA or a portion thereof.
  • the targeted therapeutic can include, for example, amino acid residues 70-952 of human GAA, or a smaller portion, such as amino acid residues 70-790.
  • a peptide tag is fused to amino acid 70, or to an amino acid within one or two positions of amino acid 70.
  • the peptide tag is a ligand for an extracellular receptor.
  • some peptide tags are targeting domains that bind an extracellular domain of a receptor on the surface of a target cell and, upon internalization of the receptor, permit localization of the therapeutic agent to a human lysosome.
  • the targeting domain includes a urokinase-type plasminogen receptor moiety capable of binding the cation-independent mannose-6-phosphate receptor.
  • the targeting domain incorporates one or more amino acid sequences of IGF-II (e.g. at least amino acids 45-55; at least amino acids 8-28 and 41-61; or at least amino acids 8-87) sequence variant thereof (e.g.
  • peptide tag is fused to the GAA polypeptide directly or by a spacer.
  • a peptide tag is fused to the GAA polypeptide by a spacer of 10-25 amino acids.
  • a peptide tag is fused to the GAA polypeptide by a spacer including glycine residues.
  • a peptide tag is fused to the GAA polypeptide by a spacer including a helical structure.
  • a peptide tag is fused to the GAA polypeptide by a spacer at least 50% identical to the sequence GGGTVGDDDDK.
  • FIGS. 1-1 to 1 - 14 depict an amino acid sequence alignment of selected members of family 31 of glycoside hydrolyases.
  • FIG. 2 is a schematic depiction of the GAA protein.
  • FIG. 3 depicts exemplary strategies for creating a peptide-tagged GAA.
  • FIG. 4 depicts an exemplary uptake experiment using wild-type GAA and SS-GAA ⁇ 1-69.
  • FIG. 5 depicts an exemplary uptake experiment using SS-GAA ⁇ 1-69 and SS-GILT ⁇ 2-7-GAA ⁇ 1-69.
  • FIG. 6 depicts an exemplary Western blot analysis of 1-87-IGF-II-tagged GAA proteins: the left panel was probed with an anti-GAA antibody; the right panel was probed with an anti-IGF-II antibody.
  • Lane 1 pCEP-GILT1-87-GAA56-952;
  • lane 2 pCEP-GILT1-87-R68A-GAA56-952-1;
  • lane 3 pCEP-GILT1-87-R68- ⁇ GS-GAA56-952-1;
  • lane 4 pCEP-GILT ⁇ 2-7-spcr1-GAA70-952-1;
  • lane 5 pCEP-GAA;
  • lane 6 pCEP-GILT-GAA29-952.
  • FIG. 7 depicts an exemplary Western blot analysis comparing proteolysis of wild-type GAA with GAA-791Asc.
  • FIG. 8 depicts an exemplary Western analysis of wild-type GAA and GAA constructs with a GILT tag engineered with a downstream Factor X protease site, GAA787GILTXa, GAA779GILTXa, and GAA796GILTXa. It also depicts a GAA C-terminal processing model.
  • GAA is a member of family 31 of glycoside hydrolyases ( FIGS. 1-1 to 1 - 14 ).
  • Human GAA is synthesized as a 110 kDal precursor (Wisselaar et al. (1993) J. Biol. Chem. 268(3):2223-31).
  • the mature form of the enzyme is a mixture of monomers of 70 and 76 kDal (Wisselaar et al. (1993) J. Biol. Chem. 268(3):2223-31).
  • the precursor enzyme has seven potential glycosylation sites and four of these are retained in the mature enzyme (Wisselaar et al. (1993) J. Biol. Chem. 268(3):2223-31).
  • the proteolytic cleavage events which produce the mature enzyme occur in late endosomes or in the lysosome (Wisselaar et al. (1993) J. Biol. Chem. 268(3):2223-31).
  • the C-terminal 160 amino acids are absent from the mature 70 and 76 kDal species.
  • certain Pompe alleles resulting in the complete loss of GAA activity map to this region, for example Val949Asp (Becker et al. (1998) J. Hum. Genet. 62:991).
  • the phenotype of this mutant indicates that the C-terminal portion of the protein, although not part of the 70 or 76 kDal species, plays an important role in the function of the protein. It has recently been reported that the C-terminal portion of the protein, although cleaved from the rest of the protein during processing, remains associated with the major species (Moreland et al. (Nov. 1, 2004) J. Biol.
  • the C-terminal residues could play a direct role in the catalytic activity of the protein.
  • the C-terminal residues may be involved in promoting proper folding of the N-terminal portions of the protein.
  • sucrase-isomaltase a related protein.
  • This family includes the sucrase-isomaltase (SI) protein which contains the two distinct but homologous glycoside hydrolyase catalytic domains in tandem on a single polypeptide. Each of these is similar to the entire GAA polypeptide in size and the two domains share 36 and 39% identity with GAA.
  • SI is expressed in intestinal brush border cells and is localized to the apical membrane of these polarized cells with the catalytic domains facing the gut lumen due to an amino-terminal trans membrane domain.
  • sucrase domain is cleaved from the amino-proximal isomaltase domain by trypsin while the isomaltase domain remains membrane associated.
  • sucrase domain is required for proper folding and subsequent transport of the isomaltase domain; sucrase is said to be an intramolecular chaperone required for the folding of the isomaltase domain (Jacob et al. (2002) J. Biol. Chem. 277:32141).
  • FIG. 2 summarizes the organization of GAA as we now understand it.
  • the precursor polypeptide possesses a signal sequence and an adjacent putative trans-membrane domain, a trefoil domain (PFAM PF00088) which is a cysteine-rich domain of about 45 amino acids containing 3 disulfide linkages and thought to be involved in protein-protein or protein carbohydrate interactions (Thim (1989) FEBS Lett. 250:85), the domain defined by the mature 70/76 kDal polypeptide, and the C-terminal domain.
  • PFAM PF00088 a trefoil domain
  • a mutation in the trefoil domain of SI has an impact on the apical membrane sorting pattern of SI (Spodsberg (2001) J. Biol. Chem. 276:23506).
  • Data presented in examples 1 and 2 indicate that both the trefoil domain and the C-terminal domain are required for the production of functional GAA. It is possible that the C-terminal domain interacts with the trefoil domain during protein folding perhaps facilitating appropriate disulfide bond formation in the trefoil domain.
  • DNA sequence encoding a peptide tag is fused in frame to the 3′ terminus of a GAA cassette that encodes the entire GAA polypeptide with the exception of the C-terminal domain.
  • This cassette is co-expressed in mammalian cells that also express the C-terminal domain of GAA as a separate polypeptide.
  • the C-terminal domain then functions in trans in conjunction with the 70/76 kDal species to generate active GAA.
  • the boundary between the catalytic domain and the C-terminal domain appears to be at about amino acid residue 791, based on its presence in a short region of less than 18 amino acids that is absent from most members of the family 31 hydrolyases and which contains 4 consecutive proline residues in GAA. Indeed, it has now been reported that the C-terminal domain associated with the mature species begins at amino acid residue 792 (Moreland et al. (Nov. 1, 2004) J. Biol. Chem., Manuscript 404008200).
  • Co-expression can be achieved by driving expression of both polypeptides from one plasmid construct introduced into mammalian cells to produce a stable cell line.
  • Expression can be driven by two promoters on such a plasmid or by one promoter driving expression of a bicistronic construct in which the two cassettes are separated by an IRES element.
  • cell lines expressing both proteins can be constructed sequentially with separate plasmids employing distinct selectable markers.
  • the peptide tag used in these fusions can be derived from IGF-II to target the CI-MPR.
  • peptide tags that preferentially bind to receptors on the surface of myotubes can be employed. Such peptides have been described (Samoylova et al. (1999) Muscle and Nerve 22:460; U.S. Pat. No. 6,329,501).
  • Other cell surface receptors, such as the Fc receptor, the LDL receptor, or the transferrin receptor are also appropriate targets and can promote targeting of GAA.
  • the cassette encoding the peptide tag is inserted into the native GAA coding sequence at the junction of the mature 70/76 kDal polypeptide and the C-terminal domain, for example at position 791. This creates a single chimeric polypeptide. Because the peptide tag may be unable to bind to its cognate receptor in this configuration, a protease cleavage site may be inserted just downstream of the peptide tag. Once the protein is produced in correct folded form, the C-terminal domain can be cleaved by protease treatment.
  • the tagged GAA can be introduced into the blood stream in a prodrug form and become activated for uptake by the serum resident protease. This might improve the distribution of the enzyme.
  • the peptide tag could be the GILT tag or a muscle-specific tag.
  • the tag is fused at the N-terminus of GAA in such a way as to retain enzymatic activity (Example 3).
  • N-terminal fusions it is possible to affect the level of secretion of the enzyme by substituting a heterologous signal peptide for the native GAA signal peptide.
  • the GAA signal peptide is not cleaved in the ER thereby causing GAA to be membrane bound in the ER (Tsuji et al. (1987) Biochem. Int. 15(5):945-952).
  • the enzyme can be found bound to the plasma membrane with retention of the membrane topology of the ER presumably due to the failure to cleave the signal peptide (Hirschhorn et al., in The Metabolic and Molecular Basis of Inherited Disease, Valle, ed., 2001, McGraw-Hill: New York, pp. 3389-3420). Sequence analysis suggests the presence of a trans-membrane domain adjacent to the signal peptide, which presumably enables the enzyme to remain membrane attached under certain conditions.
  • membrane association of GAA via its signal peptide is an important contributory factor in correct lysosomal targeting of the enzyme. This could happen in two ways: First, the membrane association could directly steer the protein to the lysosome. Second, the membrane association could increase the residence time of the GAA in the Golgi thereby increasing the level of mannose-6-phosphate added to the protein. This would have the net effect of increasing the proportion of the enzyme that is sorted to the lysosome. In either case, if this membrane association were eliminated, then more of the produced enzyme would be secreted and if the latter model were correct, the secreted enzyme would have less mannose-6-phosphate.
  • Disruption of the membrane association of GAA can be accomplished by replacing the GAA signal peptide and adjacent sequence with an alternate signal peptide for GAA.
  • the chimeric gene contains the IGF-II tag including its signal peptide fused to the N-terminus of GAA at the native signal peptide cleavage site or at appropriate downstream sites. Such a chimeric fusion will direct the production of a recombinant GAA enzyme that is secreted at high levels and that contains a high affinity ligand for the M6P/IGF-II receptor.
  • the present invention permits targeting of a therapeutic agent to a lysosome using a protein, or an analog of a protein, that specifically binds a cellular receptor for that protein.
  • the exterior of the cell surface is topologically equivalent to endosomal, lysosomal, golgi, and endoplasmic reticulum compartments.
  • endocytosis of a molecule through interaction with an appropriate receptor(s) permits transport of the molecule to any of these compartments without crossing a membrane.
  • delivery of a therapeutic protein can be achieved by tagging it with a ligand for the appropriate receptor(s).
  • a targeting portion from, for example, SV40, cholera toxin, or the plant toxin ricin, each of which coopt one or more of these subcellular trafficking pathways, a therapeutic can be targeted to the desired location within the cell.
  • uptake is initiated by binding of the material to the exterior of the cell.
  • SV40 binds to MHC class I receptors
  • cholera toxin binds to GM1 ganglioside molecules
  • ricin binds to glycolipids and glycoproteins with terminal galactose on the surface of cells.
  • the molecules reach the ER by a variety of pathways.
  • SV40 undergoes caveolar endocytosis and reaches the ER in a two step process that bypasses the golgi whereas cholera toxin undergoes caveolar endocytosis but traverses the golgi before reaching the ER.
  • a targeting moiety related to cholera toxin or ricin it is important that the toxicity of cholera toxin or ricin be avoided.
  • Both cholera toxin and ricin are heteromeric proteins, and the cell surface binding domain and the catalytic activities responsible for toxicity reside on separate polypeptides.
  • a targeting moiety can be constructed that includes the receptor-binding polypeptide, but not the polypeptide responsible for toxicity.
  • the B subunit possesses the galactose binding activity responsible for internalization of the protein, and can be fused to a therapeutic protein. If the further presence of the A subunit improves subcellular localization, a mutant version (mutein) of the A chain that is properly folded but catalytically inert can be provided with the B subunit-therapeutic agent fusion protein.
  • Proteins delivered to the golgi can be transported to the endoplasmic reticulum (ER) via the KDEL receptor, which retrieves ER-targeted proteins that have escaped to the golgi.
  • ER endoplasmic reticulum
  • KDEL receptor retrieves ER-targeted proteins that have escaped to the golgi.
  • inclusion of a KDEL motif at the terminus of a targeting domain that directs a therapeutic protein to the golgi permits subsequent localization to the ER.
  • a targeting moiety e.g.
  • an antibody, or a peptide identified by high-throughput screening such as phage display, yeast two hybrid, chip-based assays, and solution-based assays
  • a peptide identified by high-throughput screening such as phage display, yeast two hybrid, chip-based assays, and solution-based assays
  • binds the cation-independent M6P receptor both at or about pH 7.4 and at or about pH 5.5 permits targeting of a therapeutic agent to the golgi; further addition of a KDEL motif permits targeting to the ER.
  • the invention permits targeting of a therapeutic agent to a lysosome.
  • Targeting may occur, for example, through binding of a plasma membrane receptor that later passes through a lysosome.
  • targeting may occur through binding of a plasma receptor that later passes through a late endosome; the therapeutic agent can then travel from the late endosome to a lysosome.
  • a preferred lysosomal targeting mechanism involves binding to the cation-independent M6P receptor.
  • the cation-independent M6P receptor is a 275 kDa single chain transmembrane glycoprotein expressed ubiquitously in mammalian tissues. It is one of two mammalian receptors that bind M6P: the second is referred to as the cation-dependent M6P receptor.
  • the cation-dependent M6P receptor requires divalent cations for M6P binding; the cation-independent M6P receptor does not. These receptors play an important role in the trafficking of lysosomal enzymes through recognition of the M6P moiety on high mannose carbohydrate on lysosomal enzymes.
  • the extracellular domain of the cation-independent M6P receptor contains 15 homologous domains (“repeats”) that bind a diverse group of ligands at discrete locations on the receptor.
  • the cation-independent M6P receptor contains two binding sites for M6P: one located in repeats 1-3 and the other located in repeats 7-9.
  • the receptor binds monovalent M6P ligands with a dissociation constant in the ⁇ M range while binding divalent M6P ligands with a dissociation constant in the nM range, probably due to receptor oligomerization. Uptake of IGF-II by the receptor is enhanced by concomitant binding of multivalent M6P ligands such as lysosomal enzymes to the receptor.
  • the cation-independent M6P receptor also contains binding sites for at least three distinct ligands that can be used as targeting moieties.
  • the cation-independent M6P receptor binds IGF-II with a dissociation constant of about 14 nM at or about pH 7.4, primarily through interactions with repeat 11. Consistent with its function in targeting IGF-II to the lysosome, the dissociation constant is increased approximately 100-fold at or about pH 5.5 promoting dissociation of IGF-II in acidic late endosomes.
  • the receptor is capable of binding high molecular weight O-glycosylated IGF-II forms.
  • An additional useful ligand for the cation-independent M6P receptor is retinoic acid.
  • Retinoic acid binds to the receptor with a dissociation constant of 2.5 nM. Affinity photolabeling of the cation-independent M6P receptor with retinoic acid does not interfere with IGF-II or M6P binding to the receptor, indicating that retinoic acid binds to a distinct site on the receptor. Binding of retinoic acid to the receptor alters the intracellular distribution of the receptor with a greater accumulation of the receptor in cytoplasmic vesicles and also enhances uptake of M6P modified ⁇ -glucuronidase.
  • Retinoic acid has a photoactivatable moiety that can be used to link it to a therapeutic agent without interfering with its ability to bind to the cation-independent M6P receptor.
  • the cation-independent M6P receptor also binds the urokinase-type plasminogen receptor (uPAR) with a dissociation constant of 9 ⁇ M.
  • uPAR is a GPI-anchored receptor on the surface of most cell types where it functions as an adhesion molecule and in the proteolytic activation of plasminogen and TGF- ⁇ . Binding of uPAR to the CI-M6P receptor targets it to the lysosome, thereby modulating its activity.
  • fusing the extracellular domain of uPAR, or a portion thereof competent to bind the cation-independent M6P receptor, to a therapeutic agent permits targeting of the agent to a lysosome.
  • the lysosomal targeting portion is a protein, peptide, or other moiety that binds the cation independent M6P/IGF-II receptor in a mannose-6-phosphate-independent manner.
  • this embodiment mimics the normal biological mechanism for uptake of LSD proteins, yet does so in a manner independent of mannose-6-phosphate.
  • DNA encoding the mature IGF-II polypeptide can be fused to the 3′ end of an LSD gene cassette; the precursor includes a carboxyterminal portion that is cleaved in mammalian cells to yield the mature IGF-II polypeptide, but the IGF-II signal peptide is preferably omitted (or moved to the 5′ end of the LSD gene cassette).
  • This method has numerous advantages over methods involving glycosylation including simplicity and cost effectiveness, because once the protein is isolated, no further modifications need be made.
  • IGF-II is preferably targeted specifically to the M6P receptor. Particularly useful are mutations in the IGF-II polypeptide that result in a protein that binds the M6P receptor with high affinity while no longer binding the other two receptors with appreciable affinity. IGF-II can also be modified to minimize binding to serum IGF-binding proteins (Baxter (2000) Am. J. Physiol Endocrinol Metab. 278(6):967-76) to avoid sequestration of IGF-II/GILT constructs. A number of studies have localized residues in IGF-1 and IGF-II necessary for binding to IGF-binding proteins.
  • Constructs with mutations at these residues can be screened for retention of high affinity binding to the M6P/IGF-II receptor and for reduced affinity for IGF-binding proteins. For example, replacing Phe 26 of IGF-II with Ser is reported to reduce affinity of IGF-II for IGFBP-1 and -6 with no effect on binding to the M6P/IGF-II receptor (Bach et al. (1993) J. Biol. Chem. 268(13):9246-54). Other substitutions, such as Ser for Phe 19 and Lys for Glu 9, can also be advantageous.
  • Designed peptides based on the region around amino acids 48-55 can be tested for binding to the M6P/IGF-II receptor.
  • a random library of peptides can be screened for the ability to bind the M6P/IGF-II receptor either via a yeast two hybrid assay, or via a phage display type assay.
  • GILT constructs should be capable of crossing the blood brain barrier, affording for the first time a means of treating neurological symptoms associated with lysosomal storage diseases.
  • the constructs can be tested using GUS minus mice as described in Example 12.
  • IGF-II NMR structures of IGF-II have been solved by two groups (Terasawa et al. (1994) EMBO J. 13(23):5590-7; Torres et al. (1995) J. Mol. Biol. 248(2):385-401) (see, e.g., Protein Data Bank record 1IGL).
  • the general features of the IGF-II structure are similar to IGF-I and insulin.
  • the A and B domains of IGF-II correspond to the A and B chains of insulin.
  • Secondary structural features include an alpha helix from residues 11-21 of the B region connected by a reverse turn in residues 22-25 to a short beta strand in residues 26-28.
  • Residues 25-27 appear to form a small antiparallel beta sheet; residues 59-61 and residues 26-28 may also participate in intermolecular beta-sheet formation.
  • residues 59-61 and residues 26-28 may also participate in intermolecular beta-sheet formation.
  • alpha helices spanning residues 42-49 and 53-59 are arranged in an antiparallel configuration perpendicular to the B-domain helix.
  • Hydrophobic clusters formed by two of the three disulfide bridges and conserved hydrophobic residues stabilize these secondary structure features. The N and C termini remain poorly defined as is the region between residues 31 -40.
  • IGF-II binds to the IGF-II/M6P and IGF-I receptors with relatively high affinity and binds with lower affinity to the insulin receptor. IGF-II also interacts with a number if serum IGFBPs.
  • IGF-I and IGF-II share identical sequences and structures in the region of residues 48-50 yet have a 1000-fold difference in affinity for the IGF-II receptor.
  • the NMR structure reveals a structural difference between IGF-I and IGF-II in the region of IGF-II residues 53-58 (IGF-I residues 54-59): the alpha-helix is better defined in IGF-II than in IGF-I and, unlike IGF-I, there is no bend in the backbone around residues 53 and 54 (Torres et al. ( 1995 ) J. Mol. Biol. 248(2):385-401).
  • IGF-II binds to repeat 11 of the cation-independent M6P receptor.
  • a minireceptor in which only repeat 11 is fused to the transmembrane and cytoplasmic domains of the cation-independent M6P receptor is capable of binding IGF-II (with an affinity approximately one tenth the affinity of the full length receptor) and mediating internalization of IGF-II and its delivery to lysosomes (Grimme et al. (2000) J. Biol. Chem. 275(43):33697-33703).
  • the structure of domain 11 of the M6P receptor is known (Protein Data Base entries 1GP0 and IGP3; Brown et al. (2002) EMBO J.
  • the putative IGF-II binding site is a hydrophobic pocket believed to interact with hydrophobic amino acids of IGF-II; candidate amino acids of IGF-II include leucine 8, phenylalanine 48, alanine 54, and leucine 55.
  • repeat 11 is sufficient for IGF-II binding, constructs including larger portions of the cation-independent M6P receptor (e.g. repeats 10-13, or 1-15) generally bind IGF-II with greater affinity and with increased pH dependence (see, for example, Linnell et al. (2001) J. Biol. Chem. 276 (26):23986-23991).
  • the NMR structure of IGF-II shows that Thr 7 is located near residues 48 Phe and 50 Ser as well as near the 9 Cys-47 Cys disulfide bridge. It is thought that interaction of Thr 7 with these residues can stabilize the flexible N-terminal hexapeptide required for IGF-I receptor binding (Terasawa et al. (1994) EMBO J. 13 (23)5590-7). At the same time this interaction can modulate binding to the IGF-II receptor. Truncation of the C-terminus of IGF-II (residues 62-67) also appear to lower the affinity of IGF-II for the IGF-I receptor by 5 fold (Roth et al. (1991) Biochem. Biophys. Res. Commun. 181 (2):907-14).
  • the binding surfaces for the IGF-I and cation-independent M6P receptors are on separate faces of IGF-II.
  • functional cation-independent M6P binding domains can be constructed that are substantially smaller than human IGF-II.
  • the amino terminal amino acids 1-7 and/or the carboxy terminal residues 62-67 can be deleted or replaced.
  • amino acids 29-40 can likely be eliminated or replaced without altering the folding of the remainder of the polypeptide or binding to the cation-independent M6P receptor.
  • a targeting moiety including amino acids 8-28 and 41-61 can be constructed. These stretches of amino acids could perhaps be joined directly or separated by a linker.
  • amino acids 8-28 and 41-61 can be provided on separate polypeptide chains.
  • Comparable domains of insulin which is homologous to IGF-II and has a tertiary structure closely related to the structure of IGF-II, have sufficient structural information to permit proper refolding into the appropriate tertiary structure, even when present in separate polypeptide chains (Wang et al. (1991) Trends Biochem. Sci. 279-281).
  • amino acids 8-28, or a conservative substitution variant thereof could be fused to a therapeutic agent; the resulting fusion protein could be admixed with amino acids 41-61, or a conservative substitution variant thereof, and administered to a patient.
  • IGF-II tag In order to facilitate proper presentation and folding of the IGF-II tag, longer portions of IGF-II proteins can be used.
  • an IGF-II tag including amino acid residues 1-67, 1-87, or the entire precursor form can be used.
  • IGF-II and related constructs can be modified to diminish their affinity for IGFBPs, thereby increasing the bioavailability of the tagged proteins.
  • the amino acid sequence of human IGF-II may be used as a reference sequence to determine whether a candidate sequence possesses sufficient amino acid similarity to have a reasonable expectation of success in the methods of the present invention.
  • variant sequences are at least 70% similar or 60% identical, more preferably at least 75% similar or 65% identical, and most preferably 80% similar or 70% identical to human IGF-II.
  • the candidate amino acid sequence and human IGF-II are first aligned using the dynamic programming algorithm described in Smith and Waterman (1981) J. Mol. Biol. 147:195-197, in combination with the BLOSUM62 substitution matrix described in FIG. 2 of Henikoff and Henikoff (1992) PNAS 89:10915-10919.
  • an appropriate value for the gap insertion penalty is ⁇ 12
  • an appropriate value for the gap extension penalty is ⁇ 4.
  • a percent similarity score may be calculated.
  • the individual amino acids of each sequence are compared sequentially according to their similarity to each other. If the value in the BLOSUM62 matrix corresponding to the two aligned amino acids is zero or a negative number, the pairwise similarity score is zero; otherwise the pairwise similarity score is 1.0.
  • the raw similarity score is the sum of the pairwise similarity scores of the aligned amino acids. The raw score is then normalized by dividing it by the number of amino acids in the smaller of the candidate or reference sequences. The normalized raw score is the percent similarity. Alternatively, to calculate a percent identity, the aligned amino acids of each sequence are again compared sequentially.
  • the pairwise identity score is zero; otherwise the pairwise identity score is 1.0.
  • the raw identity score is the sum of the identical aligned amino acids. The raw score is then normalized by dividing it by the number of amino acids in the smaller of the candidate or reference sequences. The normalized raw score is the percent identity. Insertions and deletions are ignored for the purposes of calculating percent similarity and identity. Accordingly, gap penalties are not used in this calculation, although they are used in the initial alignment.
  • IGF-II and the cation-independent M6P receptors permit the design of IGF-II analogs and other cation-independent M6P receptor binding proteins using computer-assisted design principles such as those discussed in U.S. Pat. Nos. 6,226,603 and 6,273,598.
  • the known atomic coordinates of IGF-II can be provided to a computer equipped with a conventional computer modeling program, such as INSIGHTII, DISCOVER, or DELPHI, commercially available from Biosym, Technologies Inc., or QUANTA, or CHARMM, commercially available from Molecular Simulations, Inc.
  • the software also permits the design of peptides and organic molecules with structural and chemical features that mimic the same features displayed on at least part of the surface of the cation-independent M6P receptor binding face of IGF-II. Because a major contribution to the receptor binding surface is the spatial arrangement of chemically interactive moieties present within the sidechains of amino acids which together define the receptor binding surface, a preferred embodiment of the present invention relates to designing and producing a synthetic organic molecule having a framework that carries chemically interactive moieties in a spatial relationship that mimics the spatial relationship of the chemical moieties disposed on the amino acid sidechains which constitute the cation-independent M6P receptor binding face of IGF-II.
  • Preferred chemical moieties include but are not limited to, the chemical moieties defined by the amino acid side chains of amino acids constituting the cation-independent M6P receptor binding face of IGF-II. It is understood, therefore, that the receptor binding surface of the IGF-II analog need not comprise amino acid residues but the chemical moieties disposed thereon.
  • CAVEAT searches a database, for example, the Cambridge Structural Database, for structures which have desired spatial orientations of chemical moieties (Bartlett et al. (1989) in “Molecular Recognition: Chemical and Biological Problems” (Roberts, S. M., ed) pp 182-196).
  • the CAVEAT program has been used to design analogs of tendamistat, a 74 residue inhibitor of ⁇ -amylase, based on the orientation of selected amino acid side chains in the three-dimensional structure of tendamistat (Bartlett et al. (1989) supra).
  • GAA is expressed as a fusion protein with a peptide tag or targeting domain
  • the peptide tag can be fused directly to the GAA polypeptide or can be separated from the GAA polypeptide by a linker.
  • An amino acid linker incorporates an amino acid sequence other than that appearing at that position in the natural protein and is generally designed to be flexible or to interpose a structure, such as an ⁇ -helix, between the two protein moieties.
  • a linker can be relatively short, such as the sequence Gly-Ala-Pro or Gly-Gly-Gly-Gly-Gly-Pro, or can be longer, such as, for example, 10-25 amino acids in length.
  • FIG. 3 illustrates four exemplary strategies for creating a GILT-tagged GAA, based on the model for the organization of GAA protein as illustrated in FIG. 2 .
  • GAA amino acid residues adjacent to the fusion junction can be modified.
  • the terminal GAA cystine 952 can be deleted or substituted with serine to accommodate a C-terminal GILT tag.
  • the GILT tag can also be fused immediately preceding the final Cys952.
  • the penultimate cys938 can be changed to proline in conjunction with a mutation of the final Cys952 to serine.
  • a tag can be chemically coupled to a GAA polypeptide.
  • Preferred targeting moieties bind to their target receptors with a submicromolar dissociation constant.
  • lower dissociation constants e.g. less than 10 ⁇ 7 M, less than 10 ⁇ 8 M or less than 10 ⁇ 9 M
  • Determination of dissociation constants is preferably determined by surface plasmon resonance as described in Linnell et al. (2001) J. Biol. Chem. 276(26):23986-23991.
  • a soluble form of the extracellular domain of the target receptor e.g. repeats 1-15 of the cation-independent M6P receptor
  • the targeting moiety is passed over the chip, and kinetic and equilibrium constants are detected and calculated by measuring changes in mass associated with the chip surface.
  • any one or more of the naturally-occurring alpha-glucosidases or subcellular targeting domain, such as, for example, IGF-II, disclosed herein may be used as a reference sequence to determine whether a candidate sequence possesses sufficient amino acid similarity to have a reasonable expectation of success in the methods of the present invention.
  • variant sequences of a catalytic domain are at least 50% similar or 30% identical, preferably at least 55% similar or 35% identical, more preferably at least 60% similar or 40% identical, more preferably at least 65% similar or 45% identical, more preferably at least 70% similar or 50% identical, more preferably at least 75% similar or 55% identical, more preferably at least 80% similar or 60% identical, more preferably at least 85% similar or 65% identical, more preferably at least 90% similar or 70% identical, more preferably at least 95% similar or 75% identical, and most preferably 80% identical, 85% identical, 90% identical, or 95% identical to one of the disclosed, naturally-occurring catalytic domain of acid alpha-glucosidase.
  • Variant sequences of a chaperone domain are at least 40% similar or 20% identical, preferably at least 45% similar or 25% identical, more preferably at least 50% similar or 30% identical, more preferably at least 55% similar or 35% identical, more preferably at least 60% similar or 40% identical, more preferably at least 65% similar or 45% identical, more preferably at least 70% similar or 50% identical, more preferably at least 75% similar or 55% identical, more preferably at least 80% similar or 60% identical, more preferably at least 85% similar or 65% identical, more preferably at least 90% similar or 70% identical, more preferably at least 95% similar or 75% identical, and most preferably 80% identical, 85% identical, 90% identical, or 95% identical to one of the disclosed, naturally-occurring chaperone domain of acid alpha-glucosidase.
  • Variant sequences of a targeting domain are at least 70% similar or 60% identical, more preferably at least 75% similar or 65% identical, more preferably 80% similar or 70% identical, more preferably 85% similar or 75% identical, more preferably 90% similar or 80% identical, more preferably 95% similar or 85% identical, and most preferably, 90% identical, or 95% identical to one of the disclosed, naturally-occurring targeting domain.
  • the candidate amino acid sequence and the reference amino acid sequence are first aligned using the dynamic programming algorithm described in Smith and Waterman (1981), J. Mol. Biol. 147:195-197, in combination with the BLOSUM62 substitution matrix described in FIG. 2 of Henikoff and Henikoff (1992), “Amino acid substitution matrices from protein blocks”, PNAS (1992 Nov), 89:10915-10919.
  • an appropriate value for the gap insertion penalty is ⁇ 12
  • an appropriate value for the gap extension penalty is ⁇ 4.
  • Computer programs performing alignments using the algorithm of Smith-Waterman and the BLOSUM62 matrix such as the GCG program suite (Oxford Molecular Group, Oxford, England), are commercially available and widely used by those skilled in the art.
  • a percent similarity score may be calculated.
  • the individual amino acids of each sequence are compared sequentially according to their similarity to each other. If the value in the BLOSUM62 matrix corresponding to the two aligned amino acids is zero or a negative number, the pairwise similarity score is zero; otherwise the pairwise similarity score is 1.0.
  • the raw similarity score is the sum of the pairwise similarity scores of the aligned amino acids. The raw score is then normalized by dividing it by the number of amino acids in the smaller of the candidate or reference sequences. The normalized raw score is the percent similarity. Alternatively, to calculate a percent identity, the aligned amino acids of each sequence are again compared sequentially.
  • the pairwise identity score is zero; otherwise the pairwise identity score is 1.0.
  • the raw identity score is the sum of the identical aligned amino acids. The raw score is then normalized by dividing it by the number of amino acids in the smaller of the candidate or reference sequences. The normalized raw score is the percent identity. Insertions and deletions are ignored for the purposes of calculating percent similarity and identity. Accordingly, gap penalties are not used in this calculation, although they are used in the initial alignment.
  • administration can be oral or parenteral, including intravenous and intraperitoneal routes of administration.
  • administration can be by periodic injections of a bolus of the therapeutic or can be made more continuous by intravenous or intraperitoneal administration from a reservoir which is external (e.g., an i.v. bag).
  • the therapeutics of the instant invention can be pharmaceutical-grade. That is, certain embodiments comply with standards of purity and quality control required for administration to humans.
  • Veterinary applications are also within the intended meaning as used herein.
  • the formulations, both for veterinary and for human medical use, of the therapeutics according to the present invention typically include such therapeutics in association with a pharmaceutically acceptable carrier therefor and optionally other ingredient(s).
  • the carrier(s) can be “acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.
  • Pharmaceutically acceptable carriers are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
  • Supplementary active compounds (identified according to the invention and/or known in the art) also can be incorporated into the compositions.
  • the formulations can conveniently be presented in dosage unit form and can be prepared by any of the methods well known in the art of pharmacy/microbiology. In general, some formulations are prepared by bringing the therapeutic into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
  • routes of administration include oral or parenteral, e.g., intravenous, intradermal, inhalation, transdermal (topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
  • antibacterial agents such as benzyl alcohol or methyl parabens
  • antioxidants
  • Useful solutions for oral or parenteral administration can be prepared by any of the methods well known in the pharmaceutical art, described, for example, in Remington's Pharmaceutical Sciences, (Gennaro, A., ed.), Mack Pub., 1990.
  • Formulations for parenteral administration also can include glycocholate for buccal administration, methoxysalicylate for rectal administration, or cutric acid for vaginal administration.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • Suppositories for rectal administration also can be prepared by mixing the drug with a non-irritating excipient such as cocoa butter, other glycerides, or other compositions that are solid at room temperature and liquid at body temperatures.
  • Formulations also can include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like.
  • Formulations for direct administration can include glycerol and other compositions of high viscosity.
  • Other potentially useful parenteral carriers for these therapeutics include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • Formulations for inhalation administration can contain as excipients, for example, lactose, or can be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
  • Retention enemas also can be used for rectal delivery.
  • Formulations of the present invention suitable for oral administration can be in the form of discrete units such as capsules, gelatin capsules, sachets, tablets, troches, or lozenges, each containing a predetermined amount of the drug; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.
  • the therapeutic can also be administered in the form of a bolus, electuary or paste.
  • a tablet can be made by compressing or moulding the drug optionally with one or more accessory ingredients.
  • Compressed tablets can be prepared by compressing, in a suitable machine, the drug in a free-flowing form such as a powder or granules, optionally mixed by a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding, in a suitable machine, a mixture of the powdered drug and suitable carrier moistened with an inert liquid diluent.
  • Oral compositions generally include an inert diluent or an edible carrier.
  • the active compound can be incorporated with excipients.
  • Oral compositions prepared using a fluid carrier for use as a mouthwash include the compound in the fluid carrier and are applied orally and swished and expectorated or swallowed.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose
  • a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the composition can be sterile and can be fluid to the extent that easy syringability exists. It can be stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, and sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the therapeutic which can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension.
  • Liposomal formulations or biodegradable polymer systems can also be used to present the therapeutic for both intra-articular and ophthalmic administration.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pasts; or solutions or suspensions such as drops.
  • Formulations for topical administration to the skin surface can be prepared by dispersing the therapeutic with a dermatologically acceptable carrier such as a lotion, cream, ointment or soap.
  • a dermatologically acceptable carrier such as a lotion, cream, ointment or soap.
  • useful are carriers capable of forming a film or layer over the skin to localize application and inhibit removal.
  • the composition can include the therapeutic dispersed in a fibrinogen-thrombin composition or other bioadhesive.
  • the therapeutic then can be painted, sprayed or otherwise applied to the desired tissue surface.
  • the agent can be dispersed in a liquid tissue adhesive or other substance known to enhance adsorption to a tissue surface.
  • tissue adhesive such as hydroxypropylcellulose or fibrinogen/thrombin solutions
  • tissue-coating solutions such as pectin-containing formulations can be used.
  • inhalation of powder (self-propelling or spray formulations) dispensed with a spray can a nebulizer, or an atomizer can be used.
  • Such formulations can be in the form of a finely comminuted powder for pulmonary administration from a powder inhalation device or self-propelling powder-dispensing formulations.
  • self-propelling solution and spray formulations the effect can be achieved either by choice of a valve having the desired spray characteristics (i.e., being capable of producing a spray having the desired particle size) or by incorporating the active ingredient as a suspended powder in controlled particle size.
  • the therapeutics also can be delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Nasal drops also can be used.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Nasal drops also can be used.
  • Systemic administration also can be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants generally are known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and filsidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the therapeutics typically are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the therapeutics are prepared with carriers that will protect against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials also can be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811. Microsomes and microparticles also can be used.
  • Oral or parenteral compositions can be formulated in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • the therapeutics identified according to the invention can be formulated for parenteral or oral administration to humans or other mammals, for example, in therapeutically effective amounts, e.g., amounts which provide appropriate concentrations of the drug to target tissue for a time sufficient to induce the desired effect.
  • therapeutically effective amounts e.g., amounts which provide appropriate concentrations of the drug to target tissue for a time sufficient to induce the desired effect.
  • the therapeutics of the present invention can be administered alone or in combination with other molecules known to have a beneficial effect on the particular disease or indication of interest.
  • useful cofactors include symptom-alleviating cofactors, including antiseptics, antibiotics, antiviral and antifungal agents and analgesics and anesthetics.
  • the effective concentration of the therapeutics identified according to the invention that is to be delivered in a therapeutic composition will vary depending upon a number of factors, including the final desired dosage of the drug to be administered and the route of administration.
  • the preferred dosage to be administered also is likely to depend on such variables as the type and extent of disease or indication to be treated, the overall health status of the particular patient, the relative biological efficacy of the therapeutic delivered, the formulation of the therapeutic, the presence and types of excipients in the formulation, and the route of administration.
  • the therapeutics of this invention can be provided to an individual using typical dose units deduced from the earlier-described mammalian studies using non-human primates and rodents.
  • a dosage unit refers to a unitary, i.e. a single dose which is capable of being administered to a patient, and which can be readily handled and packed, remaining as a physically and biologically stable unit dose comprising either the therapeutic as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.
  • organisms are engineered to produce the therapeutics identified according to the invention. These organisms can release the therapeutic for harvesting or can be introduced directly to a patient. In another series of embodiments, cells can be utilized to serve as a carrier of the therapeutics identified according to the invention.
  • Therapeutics of the invention also include the “prodrug” derivatives.
  • the term prodrug refers to a pharmacologically inactive (or partially inactive) derivative of a parent molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release or activate the active component.
  • Prodrugs are variations or derivatives of the therapeutics of the invention which have groups cleavable under metabolic conditions. Prodrugs become the therapeutics of the invention which are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation.
  • Prodrug of this invention can be called single, double, triple, and so on, depending on the number of biotransformation steps required to release or activate the active drug component within the organism, and indicating the number of functionalities present in a precursor-type form.
  • Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, Calif., 1992).
  • the prodrug derivatives according to this invention can be combined with other features to enhance bioavailability.
  • the following primers were used to generate a gene cassette containing the human IGF-II signal sequence fused to human GAA residues 791-952 (the C-terminal domain).
  • GAA41 GGAATTCAGGCGCGCCGGCAGCTCCCCGTGAGCCAGCC
  • GAA 27 GCTCTAGACTAACACCAGCTGACGAGAAACTGC
  • the amplified fragment contains an Asc I site at the 5′ terminus.
  • the SS N-tag encoding the IGF-II signal sequence (residues 1-25) with an AscI site at the 3′ end was then fused at the Asc I site to the GAA C-terminal domain and the cassette was cloned in pCEP4 to generate plasmid pCEP-SS-GAA-791-952.
  • the SS N-tag nucleic acid sequence is shown as below.
  • GAA ⁇ 817-952 was generated by introducing a stop codon after amino acid residue 816. To facilitate the cloning process, the stop codon was followed by 3′ end XbaI restriction site and 5′ end contains an EcoRI restriction site. DNA and amino acid sequences of GAA ⁇ 817-952 are shown below.
  • pCEP-SS-GAA-791-952 was transfected into HEK293 cells alone as well as in combination with either plasmid pCEP-GAA ⁇ 817-952 or with pCEP-GAA ⁇ 817-952 -GILT ⁇ 1-7.
  • pCEP-GAA ⁇ 817-952 and pCEP-GAA ⁇ 817-952-GILT ⁇ 1-7 were also transfected into HEK293 cells alone. Standard transfection methods were used for the experiments. For single plasmid transfections, 1 ⁇ g of plasmid DNA was used.
  • each plasmid 0.5 ⁇ g of each plasmid were used. 1 ⁇ g of total DNA was mixed with 96 ⁇ L of HEK293 growth media lacking serum and 4 ⁇ L FuGene6 (Roche) as directed by the manufacturer. 50 ⁇ L of the mixture were added to each duplicate well of HEK293 cells growing in 12-well plates in 1 mL Dulbecco's Modified Eagles Media supplemented with 1.5 g/L sodium bicarbonate, 10% heat-inactivated FBS, and 4 mM L-glutamine. Cells were incubated 2-3 days at 37° C. in 5% CO 2 .
  • GAA activities were collected and assayed to determine GAA activities as described (Reuser, A. J., et al. (1978) Am. J. Hum. Genet. 30:132-143). No GAA activity was detected in the media collected from HEK293 cells transfected with single plasmids. By contrast, GAA activities were present in the growth media collected from HEK293 cells co-transfected with pCEP-SS-GAA-791-952 and either pCEP-GAA ⁇ 817-952 or pCEP-GAA ⁇ 817-952-GILT ⁇ 1-7 (Table 1).
  • the GAA region including amino acid residues 792-817 is present in both halves of the trans-expression constructs.
  • a pair of constructs, pCEP-GAA ⁇ 791-952-GILT ⁇ 1-7 and PCEP-SS-GAA-791-952 were designed with no overlap and the GILT tag was fused at position 791.
  • transient co-transfection experiments demonstrated that the presence of amino acid residues 792-817 within the C-terminal domain is required for efficient GAA trans-expression. TABLE 2 Amino acid residues 792-817 is required for efficient GAA trans-expression.
  • PCR was used to first generate an insertion of the nucleotide sequence GGCGCGCCG (SEQ ID NO:_) after nucleotide 2370 of the complete human GAA sequence (SEQ ID NO:_). This insertion forms an AscI restriction site preceding Ala791.
  • the GILT tag was PCR-amplified with the following DNA oligos: (SEQ ID NO:_) IGF7: gctctagaggcgcgccCTCGGACTTGGCGGGGGTAGC (SEQ ID NO:_) IGF8: ggaattcaggcgcgccgGCTTACCGCCCCAGTGAGAC
  • the amplified GILT tag contains an AscI restriction site at each terminus.
  • This GILT tag was digested with AscI and inserted into the AscI site preceding GAA Ala791 as described above. DNA sequencing confirmed the in-frame orientation of the GILT insertion.
  • This GAA cassette containing an internal GILT tag preceding Ala791 was expressed in vector pCEP4 in a plasmid named pCEP-GAA-IRGILT-4.
  • pCEP-GAA-IRGILT-4 was found to contain a PCR-generated mutation T1712C within the GAA coding sequence. This construct produced functional GAA protein.
  • N-tags A set of five tags suitable for N-terminal GAA expression (N-tags) were generated by PCR amplification using primers indicated in Table 3.
  • the GILT N-tag contains the native IGF-II signal sequence and complete GILT epitope.
  • the SS N-tag contains only the IGF-II signal sequence.
  • the GILT ⁇ 1-7 N-tag contains the IGF-II signal sequence and GILT epitope residues 8-67. It was generated with three PCR reactions: (1) PCR amplification from human IGF-II DNA template using primers IGF1 and IGF4; (2) PCR amplification from human IGF-II DNA template using primers IGF2 and IGF7; and (3) PCR amplification from the products of the first two PCR reactions using primers IGF1 and IGF7.
  • the GILT ⁇ 2-7 N-tag contains the IGF-II signal sequence, and GILT epitope residue 1 followed by residues 8-67. It was generated with three PCR reactions: (1) PCR amplification from human IGF-II DNA template using primers IGF1 and IGF5; (2) PCR amplification from human IGF-II DNA template using primers IGF3 and IGF7; and (3) PCR amplification from the products of the first two PCR reactions using primers IGF1 and IGF7.
  • the SSGAA-GILT N-tag contains the GAA signal sequence within residues 1-69, followed by the complete GILT epitope. It was generated with three PCR reactions: (1) PCR amplification from human GAA DNA template using primers GAA13 and GI1; (2) PCR amplification from human IGF-II template using primers GI2 and IGF7; and (3) PCR amplification from the products of the first two PCR reactions using primers GAA13 and IGF7.
  • N-tag contains a 5′ EcoRI restriction site and 3′ AscI and XbaI sites. The AscI site was used to fuse each tag to the GAA N-terminal deletion constructs described below. TABLE 3 N-terminal tag constructs.
  • IGF7 GCTCTAGAGGCGCCCTCGGACTTGGC GGGGGTAGC (SEQ ID NO:_)
  • SS IGF1 GGAATTCACACCAATGGGAATCC Human IGF-II CAATGG (SEQ ID NO:_)
  • IGF6 GCTCTAGAGGCGCGCCAGCAGCAATGCAG CACGAGG (SEQ ID NO:_)
  • GILT ⁇ 1-7 IGF1: GGAATTCACACCAATGGGAATCC Human IGF-II CAATGG (SEQ ID NO:_)
  • N-terminal human GAA DNA sequence Portions of the N-terminal human GAA DNA sequence were deleted and replaced with an AscI restriction site using PCR techniques.
  • 5′ DNA oligos used to define the site of deletion are listed below (Table 4). 5′ oligos were paired with various 3′ oligos within the GAA coding sequence, and the resulting DNA fragments were subsequently fused to the complete C-terminal GAA coding sequence.
  • the N-terminal AscI sites were fused to one of the five N-terminal tags (N-tags) listed above to complete the expression cassettes (Table 4). TABLE 4 GAA N-terminal deletion constructs. Sequnces complementary to GAA coding sequence are in upper case. EcoRI and AscI restriction sites are in lower case.
  • the expression cassettes listed in Table 4 contain an N-terminal tag (N-tag) fused to an N-terminal GAA deletion at a mutual AscI site.
  • the cassettes were cloned into the multiple cloning site of expression vector pCEP4 and transfected into HEK293 cells using the FuGene6 transfection reagent (Roche). Media from transient expression were collected 2-3 days post transfection and assayed for secreted GAA activity using a standard enzymatic assay (Reuser, A. J., et al. (1978) Am. J. Hum. Genet. 30:132-143). TABLE 5 Relative transient expression of N-tagged GAA constructs.
  • N-terminal portion of GAA including residues 1-80 is dispensable for transient expression, but deletions that disrupt or eliminate the trefoil domain do not produce functional protein.
  • the secretion of GAA can be improved by appropriately positioning a heterologous signal peptide, in this case the IGF-II signal peptide.
  • Positioning the IGF-II signal peptide at either residue 56 or 70 of GAA gave a three fold increase in GAA secretion compared to native GAA, while positioning the IGF-II signal peptide at position 29 did not. This may be due to the retention of a putative trans-membrane domain adjacent to the GAA signal peptide.
  • GILT tag promotes specific uptake that can be competed by IGF-II.
  • placement of the peptide tag at position 70 not only permits efficient expression of the fusion protein and GAA activity, but also provides a peptide tag that is properly folded and accessible, permitting receptor-mediated uptake into target cells.
  • GILT1-87 tag was fused to positions 56 and 70 of GAA, resulting in GILT1-87-GAA56-952 and GILT1-87-GAA70-952, respectively.
  • the DNA and amino acid sequences GILT1-87-GAA56-952 are shown below.
  • the 5′ Asp718 site was cloned into the Asp718 site of pCEP4, and the 3′Xba site was blunted with Klenow and cloned into the HindIII site of pCEP4, resulting in pCEP-GILT1-87-GAA56-952 and pCEP-GILT1-87-GAA70-952, respectively.
  • the constructs also contain Gly-Ala-Pro linker sequence (AscI site). These constructs express proteins with GAA enzymatic activity.
  • modification R68A was introduced to the GILT1-87 tag to remove a potential proteolysis site within the GILT tag (GILT1-87-R68A).
  • the DNA (SEQ ID NO:_) and amino acid (SEQ ID NO:_) sequences of GILT1-87-R68A are shown below (the mutated sequences are underlined).
  • GILT tag incorporating both R68A and ⁇ GS modifications was generated (GILT1-87-R68A- ⁇ GS).
  • GILT1-87-R68A- ⁇ GS Amino acid sequence of GILT1-87-R68A- ⁇ GS (SEQ ID NO:_).
  • the modified GILT1-87-R68A- ⁇ GS was used to generate constructs pCEP-GILT1-87-R68A ⁇ GS-GAA56-952 and pCEP-GILT1-87-R68A ⁇ GS-GAA70-952. Both constructs expressed protein with GAA enzymatic activity.
  • IGF-II In an effort to provide a native folding environment for an IGF-II tag, a precursor form of IGF-II including amino acid 8-156 was used as an internal tag fused at GAA position 791.
  • mutations E67A and D69S were made in IGF-II sequence to introduce a P2/P1 proteolysis processing site in order to promote cleavage downstream of position 87 within the IGF-II tag.
  • the resulting construct, pCEP-GAA-791IGF2-P2/P1 yields a protein with GAA enzymatic activity.
  • the DNA and amino acid sequences of pCEP-GAA-791IGF2-P2/P1 are shown below.
  • GILT tag fused at the N-terminus e.g., position 70
  • a spacer with the sequence Gly-Gly-Gly-Gly-Gly-Pro was inserted between an N-terminal GILT ⁇ 2-7 tag and the GAA fusion point position 70, yielding pCEP-GILT ⁇ 2-7-spcr1-GAA70-952.
  • This construct expressed protein with GAA enzymatic activity.
  • Constructs were made to include an insertion of Gly-Ala-Pro sequence (an AscI restriction site) within GAA region amino acid residues 783-791 according to standard molecular techniques. As indicated in Table 7, the insertion of AscI restriction site increases transient GAA enzyme expression levels. This insertion possibly could cause a shift of the enzyme to a high-affinity form. Normally the precursor GAA matures into the high-affinity GAA form after cleavage in the 783-791 boundary region (Moreland et al., 2004). It was reported that, after cleavage, the N-terminal region and the C-terminal region remain associated (Moreland et al., 2004). TABLE 7 AscI restriction site insertion increases transient expression.
  • construct pCEP-GILT ⁇ 2-7-GAA70-952-791Asc was made to combine the 791AscI site insertion with an N-terminal GILT tag at position 69.
  • GILT tags with a downstream Factor X protease site were placed within GAA at positions 787, 779, and 796. All three resulting proteins had GAA enzymatic activity.
  • Western analysis as illustrated in FIG. 8 , all three proteins contained the GILT tag as probed by an anti-IGF-II antibody. All three protein preparations contained a band with a relative mobility (M r 120,000-140,000) consistent with the presence of a full-length precursor. All three protein preparations also contained a faster migrating intermediate band (M r 85,000-100,000) which retained the GILT tag. Upon treatment of the proteins with Factor Xa, most of the full-length band is removed, and the intermediate band is shifted slightly lower. The GILT tag is retained in the Xa-treated intermediate bands.
  • FIG. 8 A possible GAA C-terminal processing model is illustrated in FIG. 8 .
  • chimeric proteins composed of N-terminal human GAA and C-terminal mouse GAA were constructed with fusion points at amino acid positions 791, 796, 816, 881, and 920 of human GAA.
  • An AscI restriction site including sequence Gly-Ala-Pro was introduced at the point of fusion.
  • chimeric human/mouse GAA proteins were made with C-terminal portions of human GAA replaced with corresponding mouse GAA C-terminal sequence.
  • DNA cassettes were constructed by fusing the human and mouse portions at a common linker sequence, ggcgcgccg, that contains a unique AscI site and encodes the sequence Gly-Ala-Pro (GAP).
  • Mouse portions of the GAA hybrid were generated by PCR with the primers listed below that contain the 5′ AscI site for fusion to the N-terminal human GAA sequence and a 3′ NotI site for cloning into the NotI site of the pCEP vector. TABLE 8 Human/Mouse GAA hybrids.
  • the chimeric GAA cassettes were transfected into HEK293 cells as described in Example 1. GAA expression levels were determined from two stable transfectants. As shown in Table 8, fusion at position 881 gives the highest enzyme expression levels. Western analysis of the position 881 fusion hybrid shows that the expressed precursor protein is of similar size to wild-type GAA. TABLE 9 Human/Mouse GAA Hybrids Expression. Stable GAA expression nmol/hr-ml Fusion position Average of two lines 791 31 796 20 816 11 881 83 920 5
  • GILT ⁇ 1-7 tag was fused to the C-terminus of each of the five full-length human/mouse hybrids listed above and the expression levels were determined in each case. Constructs were also made to combine the C-terminal position 881 mouse GAA hybrid with an N-terminal GILT tag at positions 29, 56, 70, or 81. The expression levels were determined as described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US11/057,058 2004-02-10 2005-02-10 Acid alpha-glucosidase and fragments thereof Abandoned US20050244400A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/057,058 US20050244400A1 (en) 2004-02-10 2005-02-10 Acid alpha-glucosidase and fragments thereof
US11/900,659 US7785856B2 (en) 2004-02-10 2007-09-12 Acid alpha-glucosidase and fragments thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54381204P 2004-02-10 2004-02-10
US11/057,058 US20050244400A1 (en) 2004-02-10 2005-02-10 Acid alpha-glucosidase and fragments thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/900,659 Continuation US7785856B2 (en) 2004-02-10 2007-09-12 Acid alpha-glucosidase and fragments thereof

Publications (1)

Publication Number Publication Date
US20050244400A1 true US20050244400A1 (en) 2005-11-03

Family

ID=34860468

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/057,058 Abandoned US20050244400A1 (en) 2004-02-10 2005-02-10 Acid alpha-glucosidase and fragments thereof
US11/900,659 Active 2025-02-14 US7785856B2 (en) 2004-02-10 2007-09-12 Acid alpha-glucosidase and fragments thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/900,659 Active 2025-02-14 US7785856B2 (en) 2004-02-10 2007-09-12 Acid alpha-glucosidase and fragments thereof

Country Status (11)

Country Link
US (2) US20050244400A1 (es)
EP (1) EP1716232B9 (es)
JP (1) JP4914224B2 (es)
CN (1) CN1922313B (es)
AT (1) ATE465250T1 (es)
AU (1) AU2005212435B2 (es)
CA (1) CA2553955C (es)
DE (1) DE602005020745D1 (es)
ES (1) ES2344302T3 (es)
IL (2) IL177079A (es)
WO (1) WO2005078077A2 (es)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080175833A1 (en) * 2000-07-18 2008-07-24 Duke University Treatment of glycogen storage disease type II
US20090117091A1 (en) * 2006-11-13 2009-05-07 Lebowitz Jonathan Methods for treating pompe disease
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
WO2010148253A2 (en) 2009-06-17 2010-12-23 Zystor Therapeutics, Inc. Formulations for lysosomal enzymes
WO2011163652A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
US8492338B2 (en) 2001-04-30 2013-07-23 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US8492337B2 (en) 2001-04-30 2013-07-23 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US8545837B2 (en) 2010-06-25 2013-10-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
WO2013166249A1 (en) 2012-05-03 2013-11-07 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US9220677B2 (en) 2010-06-25 2015-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
US9283181B2 (en) 2010-06-25 2016-03-15 Shire Human Genetic Therapies, Inc. CNS delivery of therapeutic agents
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
US9376480B2 (en) 2012-11-27 2016-06-28 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
WO2017147414A1 (en) 2016-02-24 2017-08-31 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
US9770410B2 (en) 2010-06-25 2017-09-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of arylsulfatase A
US10046033B2 (en) 2012-03-07 2018-08-14 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of Pompe disease
WO2018231060A1 (en) 2016-08-05 2018-12-20 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
US10208299B2 (en) 2014-09-30 2019-02-19 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
US10512676B2 (en) 2016-03-30 2019-12-24 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
US10660944B2 (en) 2011-12-23 2020-05-26 Shire Human Genetic Therapies, Inc. Stable formulations for CNS delivery of arylsulfatase A
WO2020132452A1 (en) 2018-12-20 2020-06-25 Shire Human Genetic Therapies, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
WO2020223356A1 (en) * 2019-04-30 2020-11-05 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease
US10857212B2 (en) 2015-12-30 2020-12-08 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
US11208458B2 (en) 2017-06-07 2021-12-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US11512145B2 (en) 2007-07-27 2022-11-29 Armagen, Inc. Methods and compositions for increasing alpha-L-iduronidase activity in the CNS
US11602528B2 (en) 2005-05-17 2023-03-14 Amicus Therapeutics, Inc. Method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
GB0612623D0 (en) * 2006-06-26 2006-08-02 Ares Trading Sa Proteins
CN101636200A (zh) * 2006-11-13 2010-01-27 齐斯特治疗公司 用于治疗庞贝氏症的方法
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
CA2682578C (en) 2007-04-03 2015-05-26 Oxyrane Uk Limited Glycosylation of molecules
AU2009256547B2 (en) * 2008-06-13 2014-07-10 Proyecto De Biomedicina Cima, S.L. Apo-A conjugates for the administration of biologically active compounds
JP5990102B2 (ja) 2009-09-29 2016-09-07 ユニフェルシテイト ヘント ホスホ−6−マンノースへのマンノース−1−ホスホ−6−マンノース結合の加水分解
DK2501805T3 (en) 2009-11-19 2019-04-15 Oxyrane Uk Ltd Yeast strains producing mammalian-like complex N-Glycans
KR101983572B1 (ko) 2010-09-29 2019-05-29 옥시레인 유케이 리미티드 만노스-1-포스포-6-만노스 결합의 캡핑제거 및 인산화 n-글리칸의 탈만노실이 가능한 만노시다제 및 당단백질의 활용을 통한 포유류 세포의 촉진방법
SG189110A1 (en) 2010-09-29 2013-05-31 Oxyrane Uk Ltd De-mannosylation of phosphorylated n-glycans
MX2013012345A (es) * 2011-04-22 2015-05-07 Genzyme Corp Alfa glucosidasa acida modificada con procesamiento acelerado.
BR112014022624A2 (pt) 2012-03-15 2017-07-11 Oxyrane Uk Ltd métodos e materiais para tratamento de doença de pompe
PT3292875T (pt) * 2012-06-19 2020-08-31 Univ Florida Composições e métodos para tratamento de doenças
WO2016065319A1 (en) * 2014-10-24 2016-04-28 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
EP3262056A4 (en) * 2015-02-27 2018-09-19 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
CA3003750A1 (en) 2015-11-06 2017-05-11 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
HRP20231465T1 (hr) * 2015-12-30 2024-03-01 Amicus Therapeutics, Inc. Poboljšana kisela alfa-glukozidaza za liječenje pompeove bolesti
KR102522059B1 (ko) 2016-04-18 2023-04-14 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
US11339406B2 (en) * 2016-09-12 2022-05-24 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
US10874750B2 (en) 2018-04-30 2020-12-29 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use
BR112021006829A2 (pt) 2018-10-10 2021-07-20 Amicus Therapeutics, Inc. composições de polipeptídeos estabilizados com ligações dissulfeto e métodos de uso

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329501B1 (en) * 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
US20030082176A1 (en) * 2001-04-30 2003-05-01 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040248262A1 (en) * 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309776A (en) 1980-05-13 1982-01-12 Ramon Berguer Intravascular implantation device and method of using the same
US4749570A (en) 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1986000619A1 (en) 1984-07-13 1986-01-30 Chiron Corporation Prepro insulin-like growth factors i and ii
CA1260858A (en) 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5817623A (en) 1995-03-06 1998-10-06 Univ Colorado State Res Found Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
US5248606A (en) 1990-06-11 1993-09-28 Dowelanco Dna encoding inactive precursor and active forms of maize ribosome inactivating protein
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5633235A (en) 1991-04-19 1997-05-27 Regents Of The University Of Michigan Triciribine and analogs as antiviral drugs
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5736363A (en) 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
AU2752892A (en) 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
CA2123307A1 (en) 1991-11-26 1993-06-10 Phillip M. Friden Process for the preparation of transferrin receptor specific antibody-neuro-pharmaceutical or diagnostic agent conjugates
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5981194A (en) 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US5476779A (en) 1992-09-30 1995-12-19 University Of Maryland At College Park DNA encoding insulin-like growth factor II isolated from rainbow trout
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US20020013953A1 (en) 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US20010006635A1 (en) 1995-09-29 2001-07-05 D. Clark Bennett Use of heparinase to decrease inflammatory responses
US6348194B1 (en) 1995-11-13 2002-02-19 Ixsys Incorporated Tumor specific internalizing antigens and methods for targeting therapeutic agents
US6344436B1 (en) 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
CA2244228A1 (en) 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US6020144A (en) 1996-09-12 2000-02-01 Symbiontics, Inc. Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6235874B1 (en) 1997-01-10 2001-05-22 Academia Sinica Production of biologically active recombinant insulin-like growth factor II polypeptides
EP1025521B1 (en) 1997-06-02 2007-04-11 The Johns Hopkins University Computer method utilizing free energy calculations for ligand design and the prediction of binding targets
US6472140B1 (en) 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
CA2305768A1 (en) 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
NZ510358A (en) 1998-08-11 2002-09-27 Large Scale Biology Corp Method for recovering proteins from the interstitial fluid of plant tissues
CA2353522A1 (en) 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
US6596500B1 (en) 1998-12-08 2003-07-22 The General Hospital Corporation Binding of retinoids to M6P/IGF-II receptor
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
DK174076B1 (da) 2000-01-21 2002-05-21 Flowcon Int As Reguleringsindsats til anbringelse i ventiler og ventilenhed
US20020081654A1 (en) 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
PT3449934T (pt) 2000-07-18 2020-06-25 Univ Duke Tratamento de doença de armazenanto de glicogénio tipo ii
AU2002241540A1 (en) 2000-11-30 2002-06-11 Symbiontics, Inc. Protozoan expression systems for lysosomal storage disease genes
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US20030004236A1 (en) 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IL161352A0 (en) 2001-10-16 2004-09-27 Symbiontics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
EP1463512B1 (en) 2002-01-11 2014-05-28 biOasis Technologies Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
AU2003224880A1 (en) 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
CA2487815A1 (en) * 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329501B1 (en) * 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
US20030082176A1 (en) * 2001-04-30 2003-05-01 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040248262A1 (en) * 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907839B2 (en) 2000-07-18 2018-03-06 Duke University Treatment of glycogen storage disease type II
US9370556B2 (en) 2000-07-18 2016-06-21 Duke University Treatment of glycogen storage disease type II
US10792341B2 (en) 2000-07-18 2020-10-06 Duke University Treatment of glycogen storage disease type II
US20080175833A1 (en) * 2000-07-18 2008-07-24 Duke University Treatment of glycogen storage disease type II
US8900552B2 (en) 2000-07-18 2014-12-02 Duke University Treatment of glycogen storage disease type II
US8859498B2 (en) 2001-04-30 2014-10-14 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US10300113B2 (en) 2001-04-30 2019-05-28 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US9814762B2 (en) 2001-04-30 2017-11-14 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US8492338B2 (en) 2001-04-30 2013-07-23 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US8492337B2 (en) 2001-04-30 2013-07-23 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US11602528B2 (en) 2005-05-17 2023-03-14 Amicus Therapeutics, Inc. Method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
US20090117091A1 (en) * 2006-11-13 2009-05-07 Lebowitz Jonathan Methods for treating pompe disease
US11512145B2 (en) 2007-07-27 2022-11-29 Armagen, Inc. Methods and compositions for increasing alpha-L-iduronidase activity in the CNS
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US11351231B2 (en) 2008-05-07 2022-06-07 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
EP3272773A1 (en) 2008-05-07 2018-01-24 BioMarin Pharmaceutical Inc. Lyosomal targeting peptides and uses thereof
EP3778652A1 (en) 2008-05-07 2021-02-17 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US20110223147A1 (en) * 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
EP3187508A1 (en) 2008-05-07 2017-07-05 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US8563691B2 (en) 2008-05-07 2013-10-22 Biomarin Pharmaceutical, Inc. Lysosomal targeting peptides and uses thereof
US9469683B2 (en) 2008-05-07 2016-10-18 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
US8778890B2 (en) 2009-03-31 2014-07-15 Temple University—Of the Commonwealth System of Higher Education Leptin antagonist and methods of use
EP3075386A1 (en) 2009-06-17 2016-10-05 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2010148253A2 (en) 2009-06-17 2010-12-23 Zystor Therapeutics, Inc. Formulations for lysosomal enzymes
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US9283181B2 (en) 2010-06-25 2016-03-15 Shire Human Genetic Therapies, Inc. CNS delivery of therapeutic agents
US11260112B2 (en) 2010-06-25 2022-03-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
US9814764B2 (en) 2010-06-25 2017-11-14 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b by intrathecal administration of alpha-n-acetylglucosaminidase
WO2011163652A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
US8545837B2 (en) 2010-06-25 2013-10-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
US11471516B2 (en) 2010-06-25 2022-10-18 Shire Human Genetic Therapies, Inc. CNS delivery of therapeutic agents
US9770410B2 (en) 2010-06-25 2017-09-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of arylsulfatase A
US11065308B2 (en) 2010-06-25 2021-07-20 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan n-sulfatase
US11065307B2 (en) 2010-06-25 2021-07-20 Shire Human Genetic Therapies, Inc. Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety
US9220677B2 (en) 2010-06-25 2015-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
US10646554B2 (en) 2010-06-25 2020-05-12 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of arylsulfatase A
US10456454B2 (en) 2010-06-25 2019-10-29 Shire Human Genetic Therapies, Inc. CNS delivery of therapeutic agents
US10660944B2 (en) 2011-12-23 2020-05-26 Shire Human Genetic Therapies, Inc. Stable formulations for CNS delivery of arylsulfatase A
US10046033B2 (en) 2012-03-07 2018-08-14 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of Pompe disease
US11278599B2 (en) 2012-03-07 2022-03-22 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of Pompe disease
US10512677B2 (en) 2012-03-07 2019-12-24 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of pompe disease
WO2013166249A1 (en) 2012-05-03 2013-11-07 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
EP3871688A1 (en) 2012-05-03 2021-09-01 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US9376480B2 (en) 2012-11-27 2016-06-28 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
US11254725B2 (en) 2012-11-27 2022-02-22 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
US9834587B2 (en) 2012-11-27 2017-12-05 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
US9834588B2 (en) 2012-11-27 2017-12-05 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
US9845346B2 (en) 2012-11-27 2017-12-19 BioMarin Pharmaceurical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
EP3115372A1 (en) 2012-11-27 2017-01-11 BioMarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
US10301369B2 (en) 2012-11-27 2019-05-28 Biomarin Pharmaceutical Inc. Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteins
US9771408B2 (en) 2012-11-27 2017-09-26 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
US10961522B2 (en) 2014-09-30 2021-03-30 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US11591583B2 (en) 2014-09-30 2023-02-28 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US11753632B2 (en) 2014-09-30 2023-09-12 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US10208299B2 (en) 2014-09-30 2019-02-19 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US11278601B2 (en) 2015-12-30 2022-03-22 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
US10857212B2 (en) 2015-12-30 2020-12-08 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
EP4275751A2 (en) 2016-02-24 2023-11-15 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
WO2017147414A1 (en) 2016-02-24 2017-08-31 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
US10512676B2 (en) 2016-03-30 2019-12-24 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
US11441138B2 (en) 2016-03-30 2022-09-13 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
US11491211B2 (en) 2016-03-30 2022-11-08 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
WO2018231060A1 (en) 2016-08-05 2018-12-20 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
US11208458B2 (en) 2017-06-07 2021-12-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
WO2020132452A1 (en) 2018-12-20 2020-06-25 Shire Human Genetic Therapies, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
WO2020223356A1 (en) * 2019-04-30 2020-11-05 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease

Also Published As

Publication number Publication date
DE602005020745D1 (de) 2010-06-02
ATE465250T1 (de) 2010-05-15
EP1716232A2 (en) 2006-11-02
WO2005078077A2 (en) 2005-08-25
US20080299640A1 (en) 2008-12-04
AU2005212435A1 (en) 2005-08-25
IL177079A (en) 2011-10-31
JP2007521818A (ja) 2007-08-09
CN1922313A (zh) 2007-02-28
EP1716232B1 (en) 2010-04-21
CN1922313B (zh) 2011-10-26
IL177079A0 (en) 2006-12-10
AU2005212435B2 (en) 2010-09-09
CA2553955A1 (en) 2005-08-25
ES2344302T3 (es) 2010-08-24
CA2553955C (en) 2012-08-28
US7785856B2 (en) 2010-08-31
ES2344302T9 (es) 2011-03-11
IL207446A0 (en) 2010-12-30
JP4914224B2 (ja) 2012-04-11
EP1716232B9 (en) 2010-10-13
WO2005078077A3 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
US7785856B2 (en) Acid alpha-glucosidase and fragments thereof
US7396811B2 (en) Subcellular targeting of therapeutic proteins
US10300113B2 (en) Targeted therapeutic proteins
JP2007521818A5 (es)
US8207114B2 (en) Targeted therapeutic proteins
AU2002256423A1 (en) Subcellular targeting of therapeutic proteins
AU2003237314B2 (en) Targeted therapeutic proteins

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZYSTOR THERAPEUTICS, INC., WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEBOWITZ, JONATHAN;MAGA, JOHN;REEL/FRAME:016719/0815

Effective date: 20050519

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BIOMARIN PHARMACEUTICAL INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZYSTOR THERAPEUTICS, INC.;REEL/FRAME:025846/0079

Effective date: 20110211